Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
?Part 1: To evaluate the safety and tolerability of ruxolitinib in combination with pemetrexed/cisplatin and select a dose for further evaluation ?Part 2: To evaluate and compare the OS of subjects with nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent when treated with ruxolitinib or placebo in combination with pemetrexed/cisplatin and subsequently pemetrexed maintenance
Critère d'inclusion
- Nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent,CPCNP no escamoso en estadio IIIB, estadio IV o recurrente